Medicare should provide predictable and timely pathways to coverage and reimbursement for new technologies while ensuring that there is robust evidence supporting those technologies. Potential reforms, such as eliminating the CED program, would remove key policy tools available to CMS. Instead, efforts should focus on more efficient post-market evidence generation, streamlined processes, flexible study designs, and robust data infrastructure.
